• Genomic landscape of neutrophilic leukemias of ambiguous diagnosis.

  Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW.
  Blood. 2019 Sep 12. 11(134).
  
  Data

• MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer.

  Venkateswaran N, Lafita-Navarro MC, Hao YH, Kilgore JA, Perez-Castro L, Braverman J, Borenstein-Auerbach N, Kim M, Lesner NP, Mishra P, Brabletz T, Shay JW, DeBerardinis RJ, Williams NS, Yilmaz OH, Conacci-Sorrell M.
  Genes Dev. 2019 Sep 01. 17-18(33).

• Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes.

  Mao N, Gao D, Hu W, Hieronymus H, Wang S, Lee YS, Lee C, Choi D, Gopalan A, Chen Y, Carver BS.
  Mol Cancer Ther. 2019 Sep. 9(18).
  
  Data Model Clinical Trial

• Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers.

  Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, Livitz D, Rhrissorrakrai K, Martin EE, Van Seventer EE, Hanna M, Slowik K, Utro F, Pinto CJ, Wong A, Danysh BP, de la Cruz FF, Fetter IJ, Nadres B, Shahzade HA, Allen JN, Blaszkowsky LS, Clark JW, Giantonio B, Murphy JE, Nipp RD, Roeland E, Ryan DP, Weekes CD, Kwak EL, Faris JE, Wo JY, Aguet F, Dey-Guha I, Hazar-Rethinam M, Dias-Santagata D, Ting DT, Zhu AX, Hong TS, Golub TR, Iafrate AJ, Adalsteinsson VA, Bardelli A, Parida L, Juric D, Getz G, Corcoran RB.
  Nat Med. 2019 Sep. 9(25).
  
  Data

• Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

  Bai X, Fisher DE, Flaherty KT.
  Nat Rev Clin Oncol. 2019 Sep. 9(16).

• Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers.

  Chatterjee N, Pazarentzos E, Mayekar MK, Gui P, Allegakoen DV, Hrustanovic G, Olivas V, Lin L, Verschueren E, Johnson JR, Hofree M, Yan JJ, Newton BW, Dollen JV, Earnshaw CH, Flanagan J, Chan E, Asthana S, Ideker T, Wu W, Suzuki J, Barad BA, Kirichok Y, Fraser JS, Weiss WA, Krogan NJ, Tulpule A, Sabnis AJ, Bivona TG.
  Cell Rep. 2019 Aug 27. 9(28).
  
  Data Model

• Ketone Body Signaling Mediates Intestinal Stem Cell Homeostasis and Adaptation to Diet.

  Cheng CW, Biton M, Haber AL, Gunduz N, Eng G, Gaynor LT, Tripathi S, Calibasi-Kocal G, Rickelt S, Butty VL, Moreno-Serrano M, Iqbal AM, Bauer-Rowe KE, Imada S, Ulutas MS, Mylonas C, Whary MT, Levine SS, Basbinar Y, Hynes RO, Mino-Kenudson M, Deshpande V, Boyer LA, Fox JG, Terranova C, Rai K, Piwnica-Worms H, Mihaylova MM, Regev A, Yilmaz ÖH.
  Cell. 2019 Aug 22. 5(178).

• TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.

  Goyal L, Shi L, Liu LY, Fece de la Cruz F, Lennerz JK, Raghavan S, Leschiner I, Elagina L, Siravegna G, Ng RWS, Vu P, Patra KC, Saha SK, Uppot RN, Arellano R, Reyes S, Sagara T, Otsuki S, Nadres B, Shahzade HA, Dey-Guha I, Fetter IJ, Baiev I, Van Seventer EE, Murphy JE, Ferrone CR, Tanabe KK, Deshpande V, Harding JJ, Yaeger R, Kelley RK, Bardelli A, Iafrate AJ, Hahn WC, Benes CH, Ting DT, Hirai H, Getz G, Juric D, Zhu AX, Corcoran RB, Bardeesy N.
  Cancer Discov. 2019 Aug. 8(9).

• The androgen receptor regulates a druggable translational regulon in advanced prostate cancer.

  Liu Y, Horn JL, Banda K, Goodman AZ, Lim Y, Jana S, Arora S, Germanos AA, Wen L, Hardin WR, Yang YC, Coleman IM, Tharakan RG, Cai EY, Uo T, Pillai SPS, Corey E, Morrissey C, Chen Y, Carver BS, Plymate SR, Beronja S, Nelson PS, Hsieh AC.
  Sci Transl Med. 2019 Jul 31. 503(11).
  
  Model

• CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs.

  Okimoto RA, Wu W, Nanjo S, Olivas V, Lin YK, Ponce RK, Oyama R, Kondo T, Bivona TG.
  J Clin Invest. 2019 Jul 22. 8(129).

• The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.

  Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D'Alessandro A, Culp-Hill R, d'Almeida A, Joshi SK, Rosenberg M, Tognon CE, Danilov AV, Druker BJ, Chang BH, McWeeney SK, Tyner JW.
  Cancer Discov. 2019 Jul. 7(9).
  
  Data

• FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.

  Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y, Watson PA, Davicioni E, Sboner A, Barbieri CE, Bose R, Leslie CS, Sawyers CL.
  Nature. 2019 Jul. 7765(571).
  
  Data Model

• Genomic correlates of clinical outcome in advanced prostate cancer.

  Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, De Sarkar N, Kunju LP, Tomlins S, Wu YM, Nava Rodrigues D, Loda M, Gopalan A, Reuter VE, Pritchard CC, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Kantoff PW, Taplin ME, Schultz N, deBono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL.
  Proc Natl Acad Sci U S A. 2019 Jun 04. 23(116).
  
  Data

• Engineering Multidimensional Evolutionary Forces to Combat Cancer.

  McCoach CE, Bivona TG.
  Cancer Discov. 2019 May. 5(9).

• Next-generation characterization of the Cancer Cell Line Encyclopedia.

  Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER, Barretina J, Gelfand ET, Bielski CM, Li H, Hu K, Andreev-Drakhlin AY, Kim J, Hess JM, Haas BJ, Aguet F, Weir BA, Rothberg MV, Paolella BR, Lawrence MS, Akbani R, Lu Y, Tiv HL, Gokhale PC, de Weck A, Mansour AA, Oh C, Shih J, Hadi K, Rosen Y, Bistline J, Venkatesan K, Reddy A, Sonkin D, Liu M, Lehar J, Korn JM, Porter DA, Jones MD, Golji J, Caponigro G, Taylor JE, Dunning CM, Creech AL, Warren AC, McFarland JM, Zamanighomi M, Kauffmann A, Stransky N, Imielinski M, Maruvka YE, Cherniack AD, Tsherniak A, Vazquez F, Jaffe JD, Lane AA, Weinstock DM, Johannessen CM, Morrissey MP, Stegmeier F, Schlegel R, Hahn WC, Getz G, Mills GB, Boehm JS, Golub TR, Garraway LA, Sellers WR.
  Nature. 2019 May. 7757(569).

• Dampening oncogenic RAS signaling.

  Bivona TG.
  Science. 2019 Mar 22. 6433(363).

• Strategies to Identify and Target Cells of Origin in Prostate Cancer.

  Karthaus WR, Sawyers CL.
  J Natl Cancer Inst. 2019 Mar 01. 3(111).

• Polytherapy and Targeted Cancer Drug Resistance.

  Chatterjee N, Bivona TG.
  Trends Cancer. 2019 Mar. 3(5).

• Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology.

  Sabnis AJ, Bivona TG.
  Trends Mol Med. 2019 Mar. 3(25).

• Targeting Alterations in the RAF-MEK Pathway.

  Yaeger R, Corcoran RB.
  Cancer Discov. 2019 Mar. 3(9).

• CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells.

  Edwards DK, Watanabe-Smith K, Rofelty A, Damnernsawad A, Laderas T, Lamble A, Lind EF, Kaempf A, Mori M, Rosenberg M, d'Almeida A, Long N, Agarwal A, Sweeney DT, Loriaux M, McWeeney SK, Tyner JW.
  Blood. 2019 Feb 07. 6(133).

• FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells.

  Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribeiro R, Viola SK, Edwards DK, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E.
  Elife. 2019 Feb 05. (8).
  
  Model

• Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.

  Neel DS, Allegakoen DV, Olivas V, Mayekar MK, Hemmati G, Chatterjee N, Blakely CM, McCoach CE, Rotow JK, Le A, Karachaliou N, Rosell R, Riess JW, Nichols R, Doebele RC, Bivona TG.
  Cancer Res. 2019 Feb 01. 3(79).
  
  Model

• Predicting response to BET inhibitors using computational modeling: A BEAT AML project study.

  Drusbosky LM, Vidva R, Gera S, Lakshminarayana AV, Shyamasundar VP, Agrawal AK, Talawdekar A, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, McWeeney SK, Druker BJ, Cogle CR.
  Leuk Res. 2019 Feb. (77).

• Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy.

  Carlson P, Dasgupta A, Grzelak CA, Kim J, Barrett A, Coleman IM, Shor RE, Goddard ET, Dai J, Schweitzer EM, Lim AR, Crist SB, Cheresh DA, Nelson PS, Hansen KC, Ghajar CM.
  Nat Cell Biol. 2019 Feb. 2(21).
  
  Data

• Differentiation of leukemic blasts is not completely blocked in acute myeloid leukemia.

  Agarwal A, Bolosky WJ, Wilson DB, Eide CA, Olson SB, Fan G, Druker BJ.
  Proc Natl Acad Sci U S A. 2019 Dec 03. 49(116).

• The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance.

  Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker A, Arnold J, Hecht T, Wicha M, Sears R, Rowley D, White R, Gulley JL, Lee J, Diaz Meco M, Small EJ, Shen M, Knudsen K, Goodrich DW, Lotan T, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson T, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS.
  Clin Cancer Res. 2019 Dec 01. 23(25).

• The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer.

  Yan Y, Ma J, Wang D, Lin D, Pang X, Wang S, Zhao Y, Shi L, Xue H, Pan Y, Zhang J, Wahlestedt C, Giles FJ, Chen Y, Gleave ME, Collins CC, Ye D, Wang Y, Huang H.
  EMBO Mol Med. 2019 Nov 07. 11(11).

• Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer.

  Stover EH, Baco MB, Cohen O, Li YY, Christie EL, Bagul M, Goodale A, Lee Y, Pantel S, Rees MG, Wei G, Presser AG, Gelbard MK, Zhang W, Zervantonakis IK, Bhola PD, Ryan J, Guerriero JL, Montero J, Liang FJ, Cherniack AD, Piccioni F, Matulonis UA, Bowtell DDL, Sarosiek KA, Letai A, Garraway LA, Johannessen CM, Meyerson M.
  Mol Cancer Res. 2019 Nov. 11(17).

• Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses.

  Pappas KJ, Choi D, Sawyers CL, Karthaus WR.
  J Vis Exp. 2019 Oct 24. 152().

• Acute myeloid leukemia-induced T-cell suppression can be reversed by inhibition of the MAPK pathway.

  Moshofsky KB, Cho HJ, Wu G, Romine KA, Newman MT, Kosaka Y, McWeeney SK, Lind EF.
  Blood Adv. 2019 Oct 22. 20(3).
  
  Model

• A rectal cancer organoid platform to study individual responses to chemoradiation.

  Ganesh K, Wu C, O'Rourke KP, Szeglin BC, Zheng Y, Sauvé CG, Adileh M, Wasserman I, Marco MR, Kim AS, Shady M, Sanchez-Vega F, Karthaus WR, Won HH, Choi SH, Pelossof R, Barlas A, Ntiamoah P, Pappou E, Elghouayel A, Strong JS, Chen CT, Harris JW, Weiser MR, Nash GM, Guillem JG, Wei IH, Kolesnick RN, Veeraraghavan H, Ortiz EJ, Petkovska I, Cercek A, Manova-Todorova KO, Saltz LB, Lavery JA, DeMatteo RP, Massagué J, Paty PB, Yaeger R, Chen X, Patil S, Clevers H, Berger MF, Lowe SW, Shia J, Romesser PB, Dow LE, Garcia-Aguilar J, Sawyers CL, Smith JJ.
  Nat Med. 2019 Oct. 10(25).
  
  Data Model

• Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.

  Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, Carlos A, Henson R, Lin C, Searles R, Ho H, Lam YL, Sweat R, Follit C, Jain V, Lind E, Borthakur G, Garcia-Manero G, Ravandi F, Kantarjian HM, Cortes J, Collins R, Buelow DR, Baker SD, Druker BJ, Tyner JW.
  Nat Commun. 2019 Jan 16. 1(10).
  
  Data Clinical Trial

• GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance.

  Lee E, Wongvipat J, Choi D, Wang P, Lee YS, Zheng D, Watson PA, Gopalan A, Sawyers CL.
  Elife. 2019 Jan 15. (8).
  
  Data Model

• Molecular signatures of multiple myeloma progression through single cell RNA-Seq.

  Jang JS, Li Y, Mitra AK, Bi L, Abyzov A, van Wijnen AJ, Baughn LB, Van Ness B, Rajkumar V, Kumar S, Jen J.
  Blood Cancer J. 2019 Jan 03. 1(9).

• Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.

  Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G, Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S.
  Nat Med. 2019 Jan. 1(25).
  
  Clinical Trial

• Visualization of drug target interactions in the contexts of pathways and networks with ReactomeFIViz.

  Blucher AS, McWeeney SK, Stein L, Wu G.
  F1000Res. 2019. (8).

• Targeting the evolution of drug resistance in lung cancer.

  Shah KN, Bandyopadhyay S.
  Mol Cell Oncol. 2019. 5(6).

• Human Intestinal Enteroids Model MHC-II in the Gut Epithelium.

  Wosen JE, Ilstad-Minnihan A, Co JY, Jiang W, Mukhopadhyay D, Fernandez-Becker NQ, Kuo CJ, Amieva MR, Mellins ED.
  Front Immunol. 2019. (10).

• Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.

  Digumarthy SR, Mendoza DP, Zhang EW, Lennerz JK, Heist RS.
  Cancers (Basel). 2019 Dec 17. 12(11).

• Targeting Oncogenic BRAF: Past, Present, and Future.

  Zaman A, Wu W, Bivona TG.
  Cancers (Basel). 2019 Aug 16. 8(11).

• Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.

  Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI.
  JAMA Oncol. 2019 Apr 01. 4(5).

• Mechanisms of Resistance to Immune Checkpoint Blockade.

  Liu D, Jenkins RW, Sullivan RJ.
  Am J Clin Dermatol. 2019 Feb. 1(20).

• Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

  Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N.
  Cell. 2019 Jan 10. 1-2(176).